Skip to content
DraconiticResearch
Search Sources API
186,123 studies31 sourcesUpdated 11 min ago
Peer-reviewedCC BY-NC-NDJAMA network open

Laser Therapy for Sexual Health in Breast Cancer Survivors Receiving Aromatase Inhibitors : A Secondary Analysis of a Randomized Clinical Trial

  • Sònia Anglès-Acedo1
  • Inmaculada Alonso2
  • Laura Ribera-Torres1
  • Eduard Mension1
  • Jorge Otero3
  • Carolina Herranz-Diez3
  • Ramon Farré3
  • Natalia Castrejon4
  • Sílvia Alòs4
  • Camil Castelo-Branco1
4 affiliations
  1. 1Clinic Institute of Gynecology, Obstetrics and Neonatology, Faculty of Medicine, University of Barcelona, Hospital Clínic of Barcelona, Barcelona, Spain
  2. 2Gynecology, Obstetrics and Neonatology Service, University Hospital Joan XXIII, Tarragona, Spain
  3. 3Unit of Biophysics and Bioengineering, Faculty of Medicine, University of Barcelona, Barcelona, Spain
  4. 4Department of Pathology, Hospital Clínic of Barcelona, University of Barcelona, Barcelona, Spain
Read full textCite

Related

  1. Laser Therapy for Sexual Health in Breast Cancer Survivors Receiving Aromatase Inhibitors
    Sònia Anglès-Acedo, Inmaculada Alonso, Laura Ribera-Torres +7
    JAMA Network OpenPeer-reviewedCC BY 4.0Psychiatry & mental healthCrossref
  2. 454 Second primary hematologic malignancies in melanoma survivors before and after the introduction of immune checkpoint inhibitors: a population-based SEER analysis
    Jeffrey Afrifa-Yamoah, Damilola Ologbe, Duresha Malik +5
    Journal for ImmunoTherapy of CancerPeer-reviewedCC BYImmunologyOncologyDOAJ
  3. Intracranial Hemorrhage in Patients Receiving Factor Xa Inhibitors: Challenges and Perspectives
    Ryuki Chatani
    Internal MedicinePeer-reviewedCC BY-NC-NDFull textCardiovascular medicineJ-STAGE
  4. Association of pre-existing cardiovascular disease with cardiovascular and clinical outcomes in patients receiving immune checkpoint inhibitors
    Lama Alfehaid, Ahmed S. Alanazi, Mansour Alomran +2
    Scientific ReportsPeer-reviewedCC BY-NC-ND 4.0Full textOncologyCrossref
  5. Risk of de novo immune-related adverse events in patients with cancer and autoimmune disease receiving immune checkpoint inhibitors
    Rotana M. Radwan, Grant D. Scheiffele, Wenxi Huang +9
    Communications MedicinePeer-reviewedCC BY 4.0General medicineNatureCrossref

Cite

BibTeXRIS
BibTeX
@article{anglesacedo2026laser,
  title = {{Laser Therapy for Sexual Health in Breast Cancer Survivors Receiving Aromatase Inhibitors : A Secondary Analysis of a Randomized Clinical Trial}},
  author = {Sònia Anglès-Acedo and Inmaculada Alonso and Laura Ribera-Torres and Eduard Mension and Jorge Otero and Carolina Herranz-Diez and Ramon Farré and Natalia Castrejon and Sílvia Alòs and Camil Castelo-Branco},
  journal = {JAMA network open},
  year = {2026},
  month = oct,
  url = {https://europepmc.org/article/PMC/PMC13673315},
  note = {CC BY-NC-ND},
}
RIS
TY  - JOUR
TI  - Laser Therapy for Sexual Health in Breast Cancer Survivors Receiving Aromatase Inhibitors : A Secondary Analysis of a Randomized Clinical Trial
AU  - Sònia Anglès-Acedo
AU  - Inmaculada Alonso
AU  - Laura Ribera-Torres
AU  - Eduard Mension
AU  - Jorge Otero
AU  - Carolina Herranz-Diez
AU  - Ramon Farré
AU  - Natalia Castrejon
AU  - Sílvia Alòs
AU  - Camil Castelo-Branco
PY  - 2026
DA  - 2026/10/01
JO  - JAMA network open
UR  - https://europepmc.org/article/PMC/PMC13673315
SN  - 2574-3805
ER  -